RNTX
Rein Therapeutics·NASDAQ
--
--(--)
--
--(--)
3.62 / 10
Netural
The fund flow profile scores 7.24/10, demonstrating robust fund flow characteristics. Favorable Small movements are tempered by challenging overall, block, Medium, Large, and Extra-large dynamics, supporting positive flow assessment. Analyst sentiment reflects divided analyst consensus with neutral perspective. The rating profile includes Neutral(100.0%) from 1 analytical reports, supported by 0.00 historical weighted rating.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
0%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-21
InstitutionBrookline Capital
Times predicted2
Historical Win Rate0.0%
Is money flowing into or out of RNTX?
- RNTX holds a Bearish analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 3.62/10 (Netural).
